

TECHNICAL DATA SHEET

CyFlow™ CD105 Purified Anti-Ms; Clone MJ7/18



AP974049

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD105	
Alternative Names	Endoglin	
Clone	MJ7/18	
Clonality	monoclonal	
Format	Purified	
Host / Isotype	Rat / IgG2a	
Species Reactivity	Mouse	
Negative Species Reactivity	_	
Quantity [Concentration]	0.1 mg [1 mg/ml]	
Immunogen	Inflamed mouse skin	

Specificity

The rat monoclonal antibody MJ7/18 recognizes CD105 antigen, a 90 kDa type I homodimerizing membrane glycoprotein expressed on vascular endothelial cells (small and large vessels), activated

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: <u>info@sysmex-partec.com</u>

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD105 Purified



monocytes and tissue macrophages, stromal cells of certain tissues including bone marrow, pre-B lymphocytes in fetal (bone?) marrow and erythroid precursors in fetal and adult bone marrow.

Application

Based on published sources, this antibody is suitable for the following applications:

- Flow cytometry
- Immunoprecipitation
- Western blot
- Immunohistochemistry (frozen sections)

Storage Buffer

The reagent is provided in phosphate buffered saline (PBS) solution, pH ≈7.4, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability Do not use after expiration date stamped on vial label.	

Background Information

CD105 (Endoglin) is a homodimeric transmembrane glycoprotein serving in presence of TGF β R-2 as a receptor for TGF β -1 and TGF β -3. CD105 is highly expressed on endothelial cells and promotes angiogenesis during wound healing, infarcts and in a wide range of tumours and its gene expression is stimulated by hypoxia. CD105 prevents apoptosis in hypoxic endothelial cells and also antagonizes the inhibitory effects of TGF β -1 on vascular endothelial cell growth and migration. Normal cellular levels of CD105 are required for formation of new blood vessels.

References

- Herouet C, Cottin M, LeClaire J, Enk A, Rousset F: Contact sensitizers specifically increase MHC class II expression on murine immature dendritic cells. In Vitr Mol Toxicol. 2000 Summer; 13(2):113-23.
 < PMID: 11031322 >
- Cho SK, Bourdeau A, Letarte M, Zúñiga-Pflücker JC: Expression and function of CD105 during the onset of hematopoiesis from Flk1(+) precursors. Blood. 2001 Dec 15; 98(13):3635-42.
 < PMID: 11739167 >

Contact Information:

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD105 Purified



- Warrington K, Hillarby MC, Li C, Letarte M, Kumar S: Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res. 2005 May-Jun; 25(3B):1851-64.
 < PMID: 16158917 >
- Fonsatti E, Nicolay HJ, Altomonte M, Covre A, Maio M: Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. Cardiovasc Res. 2010 Apr 1; 86(1):42625. < PMID: 19812043 >
- Rosu-Myles M, She YM, Fair J, Muradia G, Mehic J, Menendez P, Prasad SS, Cyr TD: Identification of a candidate proteomic signature to discriminate multipotent and non-multipotent stromal cells.
 PLoS One. 2012; 7(6):e38954. < PMID: 23266721 >
- Dassler K, Roohi F, Lohrke J, Ide A, Remmele S, Hütter J, Pietsch H, Pison U, Schütz G: Current limitations of molecular magnetic resonance imaging for tumors as evaluated with high-relaxivity CD105-specific iron oxide nanoparticles. Invest Radiol. 2012 Jul; 47(7):383-91. < PMID: 22659596 >

The Safety Data	Sheet for this product is	s available at www.sysmex-partec.com/services.	

Contact Information:

Rev 1.0 Date: 2016-07-15 EN CyFlow™ CD105 Purified